Last checked at 16 Apr 2021 12:22
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
| Name of person dealing (Note 1) | Barclays PLC. | |
| Company dealt in | WILLIS TOWERS WATSON PLC | |
| Class of relevant security to which the | ORD | |
| dealings being disclosed relate (Note 2) | ||
| Date of dealing | 15 April 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Class of relevant security: | ORD | ||||
| Long | Short | ||||
| Number | (%) | Number | (%) | ||
(1) | Relevant securities | ||||
1,686,942 | 1.31% | 163,372 | 0.13% | ||
|
|
|
| ||
(2) | Derivatives (other than options): |
|
|
|
|
72,359 | 0.06% | 7,100 | 0.01% | ||
|
|
|
| ||
(3) | Options and agreements to |
|
|
|
|
| purchase/sell: | 6,100 | 0.00% | 6,100 | 0.00% | |
|
|
|
| ||
| TOTAL: |
|
|
|
| |
1,765,401 | 1.37% | 176,572 | 0.14% | ||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: | Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities |
|
| ||||
(2) Derivatives (other than options) |
|
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total |
|
| ||||
| ||||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
| Purchase/sale | Number of relevant securities | Price per unit |
Purchase | 1 | 237.1800 USD |
Purchase | 2 | 238.2700 USD |
Purchase | 3 | 239.0166 USD |
Purchase | 86 | 238.2775 USD |
Purchase | 100 | 237.9300 USD |
Purchase | 100 | 238.8300 USD |
Purchase | 100 | 238.5200 USD |
Purchase | 101 | 238.3200 USD |
Purchase | 121 | 238.7729 USD |
Purchase | 180 | 237.9311 USD |
Purchase | 300 | 238.1033 USD |
Purchase | 300 | 237.8900 USD |
Purchase | 600 | 237.9900 USD |
Purchase | 700 | 238.0485 USD |
Purchase | 700 | 238.4257 USD |
Purchase | 700 | 238.3010 USD |
Purchase | 800 | 238.0325 USD |
Purchase | 900 | 238.2822 USD |
Purchase | 1,133 | 238.0449 USD |
Purchase | 1,200 | 238.0312 USD |
Purchase | 1,361 | 238.2659 USD |
Purchase | 1,513 | 238.0399 USD |
Purchase | 1,910 | 237.7932 USD |
Purchase | 2,036 | 238.2175 USD |
Purchase | 2,700 | 238.2189 USD |
Purchase | 4,304 | 238.2028 USD |
Purchase | 4,518 | 238.1965 USD |
Purchase | 6,487 | 238.0373 USD |
Purchase | 7,018 | 237.9800 USD |
Purchase | 22,602 | 238.0878 USD |
Sale | 1 | 238.6500 USD |
Sale | 2 | 238.9600 USD |
Sale | 2 | 237.9850 USD |
Sale | 2 | 238.4450 USD |
Sale | 2 | 238.4150 USD |
Sale | 3 | 238.7466 USD |
Sale | 3 | 238.5616 USD |
Sale | 3 | 238.5483 USD |
Sale | 3 | 238.2633 USD |
Sale | 4 | 238.8850 USD |
Sale | 5 | 238.2880 USD |
Sale | 7 | 238.3485 USD |
Sale | 9 | 238.2611 USD |
Sale | 44 | 238.1219 USD |
Sale | 100 | 238.5500 USD |
Sale | 100 | 238.7900 USD |
Sale | 125 | 238.5593 USD |
Sale | 350 | 238.1695 USD |
Sale | 1,460 | 237.9800 USD |
Sale | 1,490 | 237.6707 USD |
Sale | 1,706 | 237.7038 USD |
Sale | 2,124 | 238.1555 USD |
Sale | 2,276 | 238.0400 USD |
Sale | 3,116 | 238.2479 USD |
Sale | 3,594 | 238.1656 USD |
Sale | 4,600 | 238.2170 USD |
Sale | 5,135 | 237.9798 USD |
Sale | 10,000 | 238.0272 USD |
Sale | 26,310 | 238.1467 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
| Is a Supplemental Form 8 (Open Positions) attached? | YES |
| Date of disclosure: | 16 Apr 2021 |
| Contact name: | Large Holdings Regulatory Operations |
| Telephone number: | 020 3134 7213 |
| If a connected EFM, name of offeree/offeror with which connected | |
| If a connected EFM, state nature of connection |
Ap23
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)
OPEN POSITIONS (Note 1)
| Product name | Written or | Number of | Exercise | Type | Expiry |
| purchased | relevant securities | price | date | ||
| to which the option | |||||
| or derivative | |||||
| relates | |||||
Put Options | Purchased | -100 | 220.0000 | American | Jul 16, 2021 |
Call Options | Purchased | 100 | 240.0000 | American | Jul 16, 2021 |
Call Options | Purchased | 6,000 | 220.0000 | American | Jul 16, 2021 |
Put Options | Purchased | -6,000 | 200.0000 | American | Jul 16, 2021 |
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210416005254/en/
Copyright Business Wire 2021